AU’s TGA approves Enhurtu® (trastuzumab deruxtecan)

Oct 8, 2021

Australia’s TGA approved AstraZeneca’s Enhurtu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

Print Page Mail Article